KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Cardlytics (CDLX) over the last 10 years, with Q3 2025 value amounting to $44.0 million.

  • Cardlytics' Cash & Equivalents fell 3437.48% to $44.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.0 million, marking a year-over-year decrease of 3437.48%. This contributed to the annual value of $65.6 million for FY2024, which is 2857.02% down from last year.
  • Latest data reveals that Cardlytics reported Cash & Equivalents of $44.0 million as of Q3 2025, which was down 3437.48% from $46.7 million recorded in Q2 2025.
  • Over the past 5 years, Cardlytics' Cash & Equivalents peaked at $613.5 million during Q1 2021, and registered a low of $44.0 million during Q3 2025.
  • In the last 5 years, Cardlytics' Cash & Equivalents had a median value of $97.8 million in 2024 and averaged $148.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 50049.33% in 2021, then tumbled by 6605.11% in 2022.
  • Quarter analysis of 5 years shows Cardlytics' Cash & Equivalents stood at $233.5 million in 2021, then tumbled by 47.78% to $121.9 million in 2022, then dropped by 24.67% to $91.8 million in 2023, then decreased by 28.57% to $65.6 million in 2024, then crashed by 32.98% to $44.0 million in 2025.
  • Its Cash & Equivalents was $44.0 million in Q3 2025, compared to $46.7 million in Q2 2025 and $52.0 million in Q1 2025.